Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seqirus

Latest From Seqirus

Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy

The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.

Vaccines Coronavirus COVID-19

Indian Biotech In mRNA Push As COVID-19 Vaccine Moves To Phase II

Gennova Biopharma’s mRNA ambitions are taking wing as its HDT Bio-partnered self-amplifying vaccine moves to Phase II. Notably, the company will have to prove superiority to AstraZeneca/Serum Institute’s Covishield in what appears to be the first comparative study for a COVID-19 vaccine candidate in India, Scrip learns.

Research & Development Coronavirus COVID-19

Flu Vaccine Leader Seqirus Invests In Self-Amplifying mRNA

Seqirus is pursuing self-amplifying RNA, a promising but more technically complex approach which could help it compete in the next generation of flu and pandemic vaccines.

Companies Commercial

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.

Deals M & A
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register